Last quarter (Q4 2023), TRACON Pharmaceuticals's total revenue was $3.04M, an increase of Infinity% from the same quarter last year. In Q4, TRACON Pharmaceuticals's net income was $-4.31M. See TRACON Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 12.04M	$ 12.04M	-	$ 346.00K	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 12.04M	$ 12.04M	-	$ 346.00K	-	-
Operating Expense	$ 21.32M	$ 21.32M	$ 27.89M	$ 28.69M	$ 16.22M	$ 22.30M
Operating Income	$ -523.00K	$ -9.27M	$ -27.89M	$ -28.35M	$ -16.22M	$ -22.30M
Net Non Operating Interest Income Expense	$ -7.30M	$ -7.30M	$ -994.00K	$ -318.00K	$ -545.00K	$ -386.00K
Other Income Expense	$ -12.99M	$ -12.99M	$ 247.00K	$ 2.00K	$ -7.00K	$ 8.00K
Pretax Income	$ 1.19M	$ 1.19M	$ -29.14M	$ -28.67M	$ -16.77M	$ -22.67M
Tax Provision	$ -182.00K	$ -182.00K	$ -125.00K	$ -28.00K	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -12.34M	$ -3.59M	$ -29.14M	$ -28.67M	$ -16.77M	$ -22.67M
Basic EPS	-	-	-	-	$ -1.87	$ -7.47
Diluted EPS	-	-	-	-	$ -1.87	$ -7.47
Basic Average Shares	-	-	-	-	$ 8.98M	$ 3.03M
Diluted Average Shares	-	-	-	-	$ 8.98M	$ 3.03M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 21.32M	$ 21.32M	$ 27.89M	$ 28.69M	$ 16.22M	$ 22.30M
Net Income From Continuing And Discontinued Operation	$ -3.59M	$ -3.59M	$ -29.14M	$ -28.67M	$ -16.77M	$ -22.67M
Normalized Income	$ 7.57M	$ 1.00M	-	-	$ -16.77M	$ -22.67M
Interest Expense	-	-	-	-	$ 545.00K	$ 386.00K
EBIT	$ 2.38M	$ 1.19M	$ -29.14M	$ -28.35M	$ -16.23M	$ -22.29M
EBITDA	$ 9.73M	$ 8.55M	$ -28.63M	$ -28.39M	$ -16.23M	$ -22.27M

Currency in USD

TRACON Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing